Clinical and pharmacological application of multiscale multiphysics heart simulator, UT-Heart
10.4196/kjpp.2019.23.5.295
- Author:
Jun Ichi OKADA
1
;
Takumi WASHIO
;
Seiryo SUGIURA
;
Toshiaki HISADA
Author Information
1. UT-Heart Inc., Tokyo 154-0003, Japan. okada@sml.k.u-tokyo.ac.jp
- Publication Type:Review
- Keywords:
Cardiac resynchronization therapy;
Cardiotoxicity;
Computer simulation;
Drug evaluation, preclinical;
Models, cardiovascular
- MeSH:
Blood Pressure;
Cardiac Electrophysiology;
Cardiac Resynchronization Therapy;
Cardiotoxicity;
Clinical Medicine;
Computer Simulation;
Drug Discovery;
Drug Evaluation, Preclinical;
Electrocardiography;
Heart;
Humans;
In Vitro Techniques;
Ion Channels;
Models, Cardiovascular;
Relaxation;
Risk Assessment
- From:The Korean Journal of Physiology and Pharmacology
2019;23(5):295-303
- CountryRepublic of Korea
- Language:English
-
Abstract:
A heart simulator, UT-Heart, is a finite element model of the human heart that can reproduce all the fundamental activities of the working heart, including propagation of excitation, contraction, and relaxation and generation of blood pressure and blood flow, based on the molecular aspects of the cardiac electrophysiology and excitation-contraction coupling. In this paper, we present a brief review of the practical use of UT-Heart. As an example, we focus on its application for predicting the effect of cardiac resynchronization therapy (CRT) and evaluating the proarrhythmic risk of drugs. Patient-specific, multiscale heart simulation successfully predicted the response to CRT by reproducing the complex pathophysiology of the heart. A proarrhythmic risk assessment system combining in vitro channel assays and in silico simulation of cardiac electrophysiology using UT-Heart successfully predicted druginduced arrhythmogenic risk. The assessment system was found to be reliable and efficient. We also developed a comprehensive hazard map on the various combinations of ion channel inhibitors. This in silico electrocardiogram database (now freely available at http://ut-heart.com/) can facilitate proarrhythmic risk assessment without the need to perform computationally expensive heart simulation. Based on these results, we conclude that the heart simulator, UT-Heart, could be a useful tool in clinical medicine and drug discovery.
